Leishmaniasis is an infectious disease caused by protozoal parasites belonging to Leishmania
genus. Different clinical outcomes can be observed depending on the parasite species and health condition
of patients. It can range from single cutaneous lesion until deadly visceral form. The treatment of all
forms of leishmaniasis is based on pentavalent antimonials, and in some cases, the second-line drug,
amphotericin B is used. Beside the toxicity of both drugs, parasites can be resistant to antimonial in
some areas of the world. This makes fundamental the characterization of new drugs with leishmanicidal
effect. Thus, the aim of the present work was to study the leishmanicidal activity of drugs able to interfere
with ergosterol pathway (fenticonazole, tioconazole, nystatin, rosuvastatin and voriconazole)
against promastigote and amastigote forms of L.(L.) amazonensis, L.(V.) braziliensis and L.(L.) infantum,
and its impact on morphological and physiological changes in L.(L.) amazonensis or in host macrophages.
We observed that fenticonazole, tioconazole and nystatin drugs eliminated promastigote and
intracellular amastigotes, being fenticonazole and nystatin the most selective towards amastigote forms.
Rosuvastatin and voriconazole did not present activity against amastigote forms of Leishmania sp. In
addition, the drugs with leishmanicidal activity interfered with parasite mitochondrion. Although drugs
did not stimulate NO and H2O2, specially fenticonazole was able to alkalize infected host macrophages.
These results suggest well established and non-toxic antifungal drugs can be repurposed and used in
Keywords: New World Leishmaniasis, Drug repurposing, Anti-fungal drugs, Anti-hyperlipidemic drugs, Nystatin, Fenticonazole,
Rights & PermissionsPrintExport